<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67091">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01846039</url>
  </required_header>
  <id_info>
    <org_study_id>VOLXC-AP-ND-001</org_study_id>
    <nct_id>NCT01846039</nct_id>
  </id_info>
  <brief_title>JUVÉDERM VOLUMA® to Enhance the Appearance of the Asian Nose</brief_title>
  <official_title>A Prospective, Open-label Study of the Safety and Efficacy of JUVÉDERM VOLUMA® to Enhance the Aesthetic Appearance of the Asian Nose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan Medical</source>
  <oversight_info>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <authority>Australia: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open-label, observational study of the safety and efficacy of JUVÉDERM
      VOLUMA® to enhance the aesthetic appearance of the Asian nose
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assessment of Aesthetic Improvement Scale (AAIS)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Asian Nose Enhancement</condition>
  <arm_group>
    <arm_group_label>JUVÉDERM VOLUMA®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with JUVÉDERM VOLUMA®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crosslinked hyaluronic acid gel</intervention_name>
    <description>Up to 3 mL administered by intradermal injection</description>
    <arm_group_label>JUVÉDERM VOLUMA®</arm_group_label>
    <other_name>JUVÉDERM VOLUMA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asian subjects aged 20 years of age or older with dissatisfaction of their aesthetic
             appearance due to structural features of their nose

          -  Subjects who, in the opinion of the Investigator, can achieve a clinically meaningful
             aesthetic correction of their nose with VOLUMA® treatment

        Exclusion Criteria:

          -  -Subjects requiring filler treatment in or around the tip of the nose or between the
             eyebrows (glabellar region) to achieve a good aesthetic outcome

          -  prior nasal surgery, including grafts, implants or filler injection to the nose area

          -  Subjects with a history of sinusitis or rhinitis

          -  Subjects unlikely to achieve a meaningful aesthetic result with the prescribed dosage
             regimen of the study product.

          -  Subjects receiving botulinum toxin treatment for any indication within 3 months of
             the study or planning to receive botulinum toxin during the study

          -  Subjects who have previously received aesthetic treatment in the forehead, glabellar,
             and/or nose area with any dermal filler

          -  Subjects with a history of any significant adverse events caused by dermal fillers

          -  Subjects with a history of allergic responses to lidocaine or fillers

          -  Subjects who are pregnant or breastfeeding or wish to become pregnant during the
             study

          -  Subjects of child-bearing age who are not prepared to practice an adequate form of
             contraception during the course of the study

          -  Subjects with traumatic scars in the treatment area or a history of active
             inflammation, infection, cancerous lesion, or an unhealed wound in the treatment area

          -  Subjects requiring dental or oral surgery, including dental implants, during the
             study period

          -  Subjects with a history of bleeding disorders

          -  Subjects who are smokers

          -  Subjects using blood thinning products within 10 days of the screening visit

          -  Subjects with a history of connective tissue disease (e.g., rheumatoid arthritis,
             lupus, scleroderma, etc) causing skin scarring

          -  Subjects with a history of untreated epilepsy or other significant medical conditions

          -  Subjects with a history of alcoholism or drug abuse of dependence

          -  Subjects participating or likely to participate in another clinical trial within 30
             days of screening or during the 1 year period of the study

          -  Subjects with any other medical condition, which in the opinion of the Investigator,
             might compromise the subject's ability to tolerate the injection procedure or comply
             with requirements of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>May 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
